Novartis’ Cosentyx Boasts Positive Results in Pediatric Late-Stage Study

Novartis said its top-selling drug Cosentyx (secukinumab) significantly delayed time to worsening of symptoms in pediatric patients with juvenile psoriatic arthritis and enthesitis-related arthritis in a late-stage study.

The latest positive results for the blockbuster drug followed the FDA’s approval last week of Cosentyx as a treatment for pediatric psoriasis. The drug, which received EU approval for the same indication in August 2020, earned global net sales of almost $4 billion in 2020.

The company did not disclose full results from the phase 3 trial in 86 children aged two to 17 years but said it will present the data this week at the EULAR 2021 annual European Congress of Rheumatology.